FlushAway^TM Stool Collection

Improving Bowel Cancer Screening returns

McCormack Innovation (MI) was set up to address the low return rates of bowel or colorectal cancer screening programmes worldwide where most return or compliance rates around a dispappointing 50%.

According to the Department of Health Statistics, bowel cancer is the second highest cause of cancer deaths in the UK, with approximately 16,000 fatalities and 40,000 new cases diagnosed each year. The American Cancer Society estimates 140,000 new cases of colon/bowel cancer and 53,000 deaths for the year 2016.

With early detection nine out of ten lives can be saved but at this time. With present screening programmes, detection rates are determined by the low return rates.

MI identified that the main reason for these low returns is the non-existent method of stool sample collection.To this end, MI embarked upon the development of a stool collection device. The resultant product is a totally unique device, the safety and convenience of which will immediately raise return rates and reduce hospital infections, saving lives worldwide.

When used in hospitals, clinics and pharmacies (for home use), this stool collection method will greatly reduce the risk of cross contamination and resultant infections.

How to take a stool sample, safely and conveniently, especially for Crohn’s and Colitis sufferers